Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.
Abbott Laboratories's quarterly accumulated depreciation
declined
from Dec. 2025 (CHF-10,683 Mil) to Mar. 2026 (CHF-10,518 Mil) but then
increased
from Mar. 2026 (CHF-10,518 Mil) to Jun. 2026 (CHF-10,916 Mil).
Abbott Laboratories's annual accumulated depreciation
increased
from Dec. 2023 (CHF-10,186 Mil) to Dec. 2024 (CHF-10,772 Mil) but then
stayed the same
from Dec. 2024 (CHF-10,772 Mil) to Dec. 2025 (CHF-10,683 Mil).
Abbott Laboratories Accumulated Depreciation Related Terms
Abbott Laboratories Accumulated Depreciation Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Accumulated Depreciation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.
What does a Accumulated Depreciation of CHF-10,916 Mil mean?
Abbott Laboratories (XSWX:ABT) has a Accumulated Depreciation of CHF-10,916 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Abbott Laboratories and its competitors.
Is Abbott Laboratories' Accumulated Depreciation too high?
Abbott Laboratories' current Accumulated Depreciation is CHF-10,916 Mil. Overall, Abbott Laboratories has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Accumulated Depreciation compare to SYK and MDT?
Abbott Laboratories' Accumulated Depreciation of CHF-10,916 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Devices & Instruments company?
A good Accumulated Depreciation depends on the Medical Devices & Instruments industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current Accumulated Depreciation is CHF-10,916 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current Accumulated Depreciation of CHF-10,916 Mil. The stock's GF Value™ is CHF106.07, compared to a current price of CHF86.00 — trading 18.9% below its estimated fair value. The current Accumulated Depreciation is CHF-10,916 Mil. Abbott Laboratories' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Accumulated Depreciation is CHF-10,916 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of CHF86.00 is trading 18.9% below its estimated GF Value™ of CHF106.07.
Key valuation signals for XSWX:ABT:
Accumulated Depreciation: CHF-10,916 Mil
GF Value™: CHF106.07 vs. price of CHF86.00 (18.9% below fair value)
No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
78GF Score
Get the complete analysis for XSWX:ABT
Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABT has been successfully added to your 
